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ABSTRACT 
Oncolytic viruses represent a unique type of agents that combine self-amplification, lytic and 
immunostimulatory properties against tumors. A local and locoregional clinical benefit has been 
demonstrated upon intratumoral injections of an oncolytic herpes virus in melanoma patients, 
leading to its approval in USA and Europe for patients without visceral disease (up to stage 
IVM1a). However, in order to debulk and change the local immunosuppressive environment of 
tumors that cannot be injected directly, oncolyitc viruses need to be administered systemically. 
Among different viruses, adenovirus has been extensively used in clinical trials but with few 
evidences of activity upon systemic administration. Preclinical efficacy of a single intravenous 
administration of our oncolytic adenovirus ICOVIR5, an adenovirus type 5 responsive to the pRB 
pathway commonly deregulated in tumors, led us to use this virus in a dose-escalation phase I 
trial in metastatic melanoma patients. The results in 12 patients, treated with a single infusion of 
a dose up to 1E13 viral particles, show that ICOVIR5 can reach melanoma metastases upon a 
single intravenous administration but fails to induce tumor regressions. These results support the 




Malignant Melanoma represents the ninth most common tumor in Europe with more than 
100,000 new cases registered in 2012. 1 In advanced stages, the only approved chemotherapy is 
Dacarbazine whose response rate is around 10 %. 2 Recently, several treatments have been 
approved which are specifically targeting melanoma tumors with BRAF V600E or V600K mutations 
or blocking some forms of MEK. 3-5 Immune checkpoint blockers, ipilimumab, pembrolizumab and 
nivolumab, are also treatments recently approved due to their ability to improve overall survival. 
6-8 In addition, Talimogene laherparepvec (T-VEC), a genetically modified oncolytic herpes simplex 
virus type 1, which secrets granulocyte-macrophage colony stimulating factor, is approved for 
local intralesional injection based on data that demonstrated shrinkage of lesions, showing the 
plausibility of a strategy based on oncolysis and immune system stimulation by viruses. 9  
Oncolytic adenovirus-based therapy remains a promising approach to cancer treatment, as virus 
can infect tumor cells and selectively replicate in them, leading to oncolysis, and release of new 
viruses, which conduct to local and bloodstream spread and finally, induction of an immune 
reaction against the tumor. 10, 11 The existing experience with intravenous administration of 
oncolytic virus shows that high doses of adenovirus (≥ 1013 viral particles) in more than 300 
cancer patients resulted in limited efficacy with mild toxicity characterized by a transient febrile 
peak, elevation of transaminases, and occasionally moderate transient nausea and flu-like 
symptoms.  
ICOVIR-5 derives from the oncolytic adenovirus Ad- 24RGD 12, which contains two modifications 
compared to wild type Ad5: first, the E1A region responsible for pRB protein binding is deleted to 
abrogate the capability of E1A to release E2F from the pRB-E2F complex, characteristic of 
quiescent cells, contributing to the preferential replication of the virus in tumor and dividing cells.  
Second, an RGD sequence inserted at the HI loop of the fiber knob to target integrins at the 
surface of cancer cells as a primary receptor for virus entry. Two additional modifications were 
present in ICOVIR-5 13: replacement of the E1A promoter by the human E2F-1 promoter (insulated 
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from the E1A enhancer using the myotonic dystrophy insulator (DM-1)) and a consensus Kozak 
sequence inserted before the first codon of the E1A gene to boost E1A mRNA translation.  
The main objective of this first-in-human study was to determine the maximum tolerated dose 
(MTD) of the infusion of conditionally replicating oncolytic adenovirus ICOVIR-5 in patients with 
advanced malignant melanoma. Secondary objectives were recommended dose, safety, toxicity 
profile, and preliminary efficacy data if any. 
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MATERIALS AND METHODS 
This phase I trial of ICOVIR-5 was conducted at the Catalan Institute of Oncology (Barcelona, 
Spain) in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice, 
and it was approved by The Clinical Research Ethics Committee of the Bellvitge University 
Hospital and the Spanish Medicines and Sanitary Products Agency (AEMPS). All participants 
provided written informed consent. This study was registered at clinicaltrials.gov with the 
identifier NCT01864759.  
 
Patients 
Eligible patients had uveal or cutaneous metastasic malignant melanoma. Patients could have 
received any prior treatment for metastatic disease. Inclusion criteria were histological proof of 
cancer, age ≥ 18 years, performance status 0 to 2 (Eastern Cooperative Oncology Group [ECOG] 
scale), absolute neutrophil count (ANC) greater than or equal to 1,500/L, platelet count greater 
than or equal to 100,000/L, normal function of the liver (bilirubin level < the upper limits of 
normal [ULN], AST/ALT level  2.5 times the ULN, alkaline phosphatase level < 2.5 times the ULN) 
and kidney (creatinine clearance ≥ 50 ml/min), and negative HIV serology. Patients with previous 
participation in studies with adenovirus, viral syndrome diagnosed two weeks before inclusion, 
concomitant chronic immunosuppressant medication, concomitant malignant hematology 
disease, Li Fraumeni Syndrome or germ known deficit pRb pathway were excluded. 
 
Study Design 
The study was conducted using an accelerated escalating phase I design with cohorts of 1 patient 
if no grade >2 toxicity was found, and then with 3-6 patient cohorts after the first grade 3 toxicity 
finding. A Dose-Limiting Toxicity (DLT) observation period of 4 weeks was established before the 
entry of the first patient at the next dose level. If one out of three patients experienced DLT 
during the treatment cycle, at least one more additional patient was to be treated at this dose 
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level and up to 6 patients could be sequentially treated at this dose level. The Maximum 
Tolerated Dose (MTD) was defined as the dose level at which two of the three to six treated 
patients experienced DLT and the recommended dose (RD) was the highest dose level at which 
less than 2 of 6 patients experienced DLT. Toxicity was classified according to the Common 
Toxicity Criteria of the National Cancer Institute (NCI CTC, version 3.0). Dose Limiting Toxicity was 
defined as: ANC <0.5 x 109 / L for more than 5 days, febrile neutropenia as defined by the NCI CTC 
3.0, platelet count <25 x 109 / L, any other non-hematologic grade 3-4 toxicity except for alopecia, 
nausea/vomiting unresponsive to specific treatment, or any toxicity grade 2 unrecovered at 6 
weeks of treatment. 
 
Treatment 
ICOVIR-5 was administered as a single infusion in an inpatient regimen. Before administration, 
ICOVIR-5 was thawed and diluted in 50ml 0.9% NaCl for intravenous administration. Patients 
were monitored in a specific isolation room at the hospital until acute events were solved. 
Dose levels: 1a, 1x1011 viral particles (vp); 2a, of 3.3x1011vp; 3a, of 1x1012vp; 4a, of 3.3x1012vp and 
5a, of 1x1013vp. A dose level of 1x1010 (-1a) was planned if dose 1a became limiting.  
  
Study assessments 
All patients were evaluated by physical examination, ECG and chest X-ray. Complete blood cell 
(CBC) count, liver, and kidney function tests and urine analysis were obtained before treatment, 
on days 1, 2, 3, 5, 12, 19, and at the end of the study (day 26). Study of extent of disease was 
performed by computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, liver 
and abdomen, and bone scan with X-ray if hot spots were observed. Assessments of tumor 
lesions were made at 4 weeks of treatment applying the criteria recommended for evaluation of 
response in solid tumors (RECIST 1.1). Tumor biopsies were obtained if feasible at the beginning 




ICOVIR-5 has been previously described. 13 It derives from the oncolytic adenovirus Ad- 24RGD 
12, currently in clinical trials against glioblastoma under the name DNX-2401 (by DNAtrix 
Therapeutics, Houston Tx).   ICOVIR-5 was constructed by homologous recombination in bacteria 
and transfection in HEK293 cells. Then, it was plaque-purified and amplified in A549 cells, and 
purified using a CsCl gradient. The viral genomic structure was verified by restriction analysis. The 
DM-1 insulator, E2F-1 promoter, Kozak sequence, E1A- 24 deletion, and RGD fiber were 
sequenced. The clinical batch of ICOVIR-5 was manufactured at the Center for Cell & Gene 
Therapy at Baylor College of Medicine (Houston, TX, USA) under GMP conditions using A549 cells. 
Virus titer was adjusted to 1x1012 vp/ml in 20 mM Tris pH 8.0, 25 mM NaCl, 2,5% glycerol, 
aliquoted in sterile vials, and stored at -80 oC with continuous monitoring of temperature. 
Functional virus titer was 5.33x1010 plaque-forming units (PFU) / ml, which corresponds to 18.7 
virus particle / functional particle bioactivity ratio. No wild type Ad5 or other adventitious viruses 
were detected by PCR.  
 
Virus pharmacokinetics 
Immediately after the end of virus administration (time 0), and at 30min, 1h, 2h, 4h, 6h, and 24h 
after virus administration, blood samples were taken using 4ml Lithium Heparin Vacuette tubes 
(Greiner Bio-One, Monroe, NC, USA) and total DNA was isolated by the QIAamp DNA Mini and 
QIAamp DNA Blood Mini Kits (QIAGEN, Valencia, CA) in triplicate according to the manufacturer 
protocol. Four microliters of DNA were used to quantify genome copy number by Quantitative 
Real Time-PCR using ICOVIR-5 specific primers (ICO5F2-5’-GAT TTG GCG CGT AAA AGT G -3' which 
overlaps E2F1 promoter and the reverse ICO5R2-5'-CGG CCA TTT CTT CGG TAA TA -3' which 
overlaps with the E1A gene, generating a 126 bp amplicon). Real Time PCR consisting of 10 min at 
95 oC and 40 cycles (95 oC, 15 s; 60 oC s; 72 oC, 10 s) was performed on the LightCycler® 480 II 
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(Roche, Basel, Switzerland), using LightCycler 480  SYBR Green I Master (Roche) and analyzed with 
LightCycler® 480 Software release 1.5.0 SP4 (Roche). A control PCR without DNA was included to 
monitor reagent contamination. 
For genome copy quantification, blood from a donor was spiked with a 10-fold serial dilution of 
ICOVIR-5 to generate a standard curve from 1x1010 vp/ml to 1x102 vp/ml. This curve and negative 
controls of blood without virus were processed with the same protocol as patient samples and 
analyzed in the same Real Time PCR to quantify genome copies. Precision, accuracy, and limits of 
detection (LOD) and quantification (LOQ) were established using the standard curve in a previous 
experiment. LOD, the lowest concentration of genomes in the standard curve that can be 
detected, was 1x103 genomes/ml. LOQ, the lowest concentration of genomes in the standard 
curve which maintains linearity with the standard curve (slope 0.8-1.2), was 1x104 genomes/ml.  
 
Analysis of virus shedding 
Blood, urine, sputum, and stool samples were collected before administration and on days 1, 2, 5, 
12, 19, and 26 post-treatment. Samples were analyzed when available due to compliance of 
protocols. Among them, sputum and stool presented a higher frequency of lack of compliance. 
DNA was extracted with the following kits: QIAamp DNA Mini and QIAamp DNA Blood Mini Kits 
for blood; QIAamp Viral RNA Mini kit for urine after concentration with Millipore Amicon Ultra 
Centrifugal Filters Ultracel 50k (Millipore; Darmstadt, Germany); QIAampMinElute Virus Spin for 
sputum; and QIAamp DNA Stool for stool (all kits from QIAGEN). All samples were processed in 
triplicate.  
A 10-fold serial dilution standard curve for each type of sample was generated diluting ICOVIR-5 
in the corresponding sample obtained from non-treated donors. Standard curves and negative 
controls (samples without virus) were processed as patient samples. 
Isolated DNA (4 microliters) were used to quantify the genome copy number using the same 
Quantitative Real Time-PCR program described above for pharmacokinetics. 
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The LOQ and LOD were previously determined for the different samples. For blood, LOQ and LOD 
were the same described above for pharmacokinetics. For urine, LOQ and LOD were established 
as 1.25x104 genomes/ml. For sputum, LOD 1x103 genomes/ml and LOQ was 1x104 genomes/ml.  
For stool LOD was 1x103 genomes/g and LOQ was 1x104 genomes/g. 
 
ICOVIR-5 genomes in tumor biopsies 
Patient tumor biopsies were obtained when possible by core needle biopsy (CNB) from accessible 
skin lesions at day 5 post-treatment to detect ICOVIR-5. Samples were digested with proteinase K 
and DNA extracted using QIAamp DNA Mini and QIAamp DNA Blood Mini Kits according to the 
manufacturer instructions. A 10-fold serial dilution standard curve was generated diluting ICOVIR-
5 with sterile phosphate buffered saline (PBS, Life Technologies, Carlsbad, CA, USA) and 
processed as tumor samples. 
Isolated DNA (4 microliters) were used to quantify the genome copy number using the same 
Quantitative Real Time-PCR program as above for pharmacokinetics. The LOD was 
103genomes/sample and the LOQ 104genomes/sample. 
 
Analysis of cytokines in blood. 
Cytokines IL-6 and IL-10 were chosen for the analysis as possible predictors of immunologic 
response and toxicity. Basal and post-treatment levels (6h, 24h, 48h, day 5, day 12, day 19, and 
day 26) of cytokines IL-6 and IL-10 in patient serum were quantified using ELISA assays (R&D; 
Minneapolis, MN, USA). Patient peripheral blood was collected in Vacuette Z Serum Sep Clot 
Activator tubes (Greiner Bio-One, Monroe, NC, USA), allowed to coagulate for 30 minutes and 
centrifuged at 1500 g for 10 minutes. Serum samples were harvested and stored at –80 oC until 
analysis. ELISA assays were carried out according to manufacturer’s protocols. Each sample was 
analyzed in triplicate.  
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Anti-ICOVIR-5 neutralizing antibodies 
Neutralizing antibodies in serum against adenovirus type 5 were analyzed before treatment and 
at day 19 after ICOVIR-5 administration. Samples of serum were heated at 56 °C for 30 minutes in 
order to inactivate complement. A 2-fold serial dilution of inactivated samples from 1/10 to 
1/5120 was performed in Dulbecco’s modified Eagle’s medium in 96-well plates (final volume 50 
l) in quadruplicates. Serum dilutions were incubated for 1h at room temperature with 2.5x104 
transducing units (TU) of AdTL, an adenovirus type 5 E1-deleted vector expressing luciferase and 
enhanced green fluorescent protein (EGFP). 14 Afterwards, 1x105 HEK-293 cells per well were 
added (to obtain a proportion or multiplicity of infection of 0.25 TU/cell) and cultured at 37 °C 
and 5% CO2. After 24h of infection, media was removed and cells washed once with PBS. Finally, 
the level of luciferase in each sample was quantified using a Victor X5 Multilabel Plate Reader 
(PerkinElmer, Waltham, MA, USA). The percentage of neutralization was calculated with the 
formula (% neutralization = [1-((LUsample-LUnegative control)/(LUpositive control-LUnegative 
control))] x 100. 
As a negative control we used the luciferase units (LU) of a non-infected well and as a positive 
control we used the LU of an infected well without serum. The neutralizing antibody titers were 
expressed as the reciprocal of the serum dilution closest to 50% neutralization of the infection. 
Every serum sample was quantified in quadruplicate.  
 
Statistical analysis  
Descriptive statistics were used for safety analyses for all patients who received one dose of 
ICOVIR-5. Categorical and continuous data were summarized with frequencies and percentages. 
The efficacy population included all patients with a baseline assessment and a post-baseline 
tumor assessment. Fisher´s exact test was used to correlate neutralizing antibodies with clinical 
responses and linear regression analysis to correlate viral doses with cytokine levels.  
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RESULTS 
Patient characteristics, tolerability, and efficacy 
Thirteen patients were enrolled in the study and twelve were treated at five dose levels (Table 1). 
Patient #05 was screened but not treated due to early progression. All 12 treated patients were 
evaluable for toxicity. Patients’ characteristics were as follows: 7 males and 5 females; the median 
age was 51 (range 40-80) and the ECOG performance status was 0 (5 patients) or 1 (7 patients).  
All patients had evaluable or measurable disease. Six patients (50%) had received at least one 
prior chemotherapy regimen for metastatic melanoma, and 4 (33%) patients had received 
previous immunotherapy (supplementary table 1). Six patients had uveal melanoma and six 
cutaneous melanoma. All patients received one treatment injection and were observed for 4 
weeks, except for one (#02) who did not complete one cycle of observation due to early 
progression. This patient #02, following the protocol, was replaced, although he was considered 
evaluable for toxicity. The patient, in the context of a rapid progression, presented a 
disseminated intravascular coagulation (DIC) not related to the treatment but to the progression 
of the underlying disease.  
Table 2 lists the most significant all-cycle non-hematological toxicities observed in the study. At 
dose levels 1a to 3a no relevant toxicity was observed. The grade 2 toxicity observed at level 4a 
allowed to proceed to dose escalation. Acute toxicity was mainly a flu-like syndrome with fever, 
chills, arthromyalgia, headache, nausea and vomiting, and diarrhea, which began in the first 4-6 
hours after infusion and during 2-4 days. The first patient at the level 5a (patient #08) 
experienced toxicity as transaminitis grade 3 at day +1. In addition, this patient presented grade 3 
thrombocytopenia at day +4. On day +2, transaminitis was recovered to grade 1 and 
thrombocytopenia lasted to day +12.  This dose level was then expanded to 6 patients. Patient 
#13 presented the second DLT as hepatic grade 3 toxicity (grade 3 AST elevation which lasted two 
days and recovered to grade 0 at day +12). Both patients had normal transaminases level before 
treatment, and only patient #08 had metastatic liver involvement at the beginning of the study. 
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According to protocol, this level (5a: 1x1013) was declared MTD, and the recommended phase 2 
dose was defined at the inferior dose level 4a (3.3x1012). Other significant toxicities at this dose 
level included: grade 2 neutropenia in patient #08 and grade 2 AST elevation in both patients. 
With regard to efficacy, the eleven patients who had received treatment and had undergone at 
least one disease evaluation (performed day 26) were evaluated. No objective responses, partial 
or complete, were observed. At the lower dose levels two patients had stable disease, patient #03 
until day 100 post-treatment and patient #06 until day 433 after treatment. At the highest dose 
level (1x1013 vp) stable disease was observed in 5 out of 6 patients, patient #09 until day 56, 
patient #010 until day 94, patient # 11 until day 131, patient # 12 until day 84, and patient #013 
until day 112 post-treatment (Table 3). Comparing the survival of cutaneous melanoma patients 
that never received targeted therapy or anti-PD1 antibodies after participating in the trial versus 
uveal melanoma patients, the survival probability was 3.7 times longer for the uveal melanoma 
patients  (Supplementary figure 1. Median 271 days for uveal vs 73 days for cutaneous, HR 0.15; 
95% CI 0.026-0.85).  
 
Neutralizing antibodies 
The levels of Anti-Ad5 neutralizing antibodies were analyzed before treatment and day 19 post-
treatment in sera (Table 3). All patients developed an antiviral immune response as shown by the 
increase of neutralizing antibodies after virus administration regardless of the basal level and the 
dose of ICOVIR-5 administered. The increase of titer did not correlate with the dose of ICOVIR-5 
administered. Only the three patients with lower basal levels of NAbs did not reach the upper 
limit of quantification (>5120). Finally, for the highest dose cohort, where stable diseases were 
seen, no correlation was observed between the pre-existence of basal neutralizing antibodies and 




Pharmacokinetics of ICOVIR-5 in patients’ blood was monitored for the first 24h post-
administration by Quantitative Real Time-PCR using the specific set of primers for the ICOVIR-5 
genome. The level of ICOVIR-5 in blood correlated with the dose administered (Fig 1). Patient #01 
treated with 1x1011vp and patient #03 treated with 3.3x1011vp had circulating viral genomes up to 
1h (1.69x104genomes/ml) and 6h (2.85x104genomes/ml) post-administration, respectively 
(patient #01 had detectable but not quantifiable at 6h), with no evidence of viral genomes in 
blood after 24h post-administration. Patient #06 treated with 1x1012vp had quantifiable viral 
genomes at 6h post-administration (1.56x105genomes/ml) and detectable levels at 24h post-
administration. Patient #07 administered with 3.3x1012vp showed quantifiable viral genomes at 
24h post-treatment (3.61x104genomes/ml). Finally, 5 out of the 6 patients of the last cohort 
(treated at 1x1013vp) had quantifiable virus genomes at 24h post-treatment 
(9.18x105genomes/ml ± 8.67x105 genomes/ml), with only one patient (patient #08) with 
detectable but not quantifiable levels at this time point. 
 
Virus shedding 
In all patients from the lower dose levels (one patient per each dose of 1x1011, 3.3x1011, and 
1x1012vp) ICOVIR-5 genomes could not be detected in any of the samples analyzed (blood, urine, 
sputum, and stool). 
In patient #07 treated with 3.3x1012vp virus DNA was detected in blood (although not 
quantifiable) and in sputum (3.96x103 genomes/ml) at 48h post-treatment. Both types of samples 
became negative for the presence of virus in the next time point analyzed, at 5 days post-
treatment, and remained negative.  
In patients treated at the highest dose level (1x1013vp) an increase in the virus shedding was 
detected (Fig 2). In blood, 24h post-treatment 5 out of the 6 patients presented quantifiable viral 
genomes (9.18x105genomes/ml ± 8.67x105genomes/ml) and one patient (patient #08) presented 
detectable but not quantifiable levels. At 48h post-treatment, 4 out of 5 patients had quantifiable 
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virus genomes (2.90x105genomes/ml ± 3.70x105genomes/ml) and one patient (patient #08) had 
detectable but not quantifiable levels. At 5 days post-treatment, 4 out of 6 patients had 
quantifiable viral genomes (8.64x105genomes/ml ± 9.94x105genomes/ml) and the remaining 2 
patients (patients #08 and #10) had detectable but not quantifiable levels. Virus genomes could 
be detected up to day 6 (patients #08 and #11) or day 8 (patients #09 and #10) after virus 
administration. Surprisingly, in the remaining 2 patients (patients #012 and #013), virus genomes 
were detected until the end of the treatment (day 26 after virus administration). In urine, virus 
DNA was detected only in patient #09. This patient had 1.16x106genomes/ml at 24h, 
1.51x105genomes/ml at 48h, and 2.16x105genomes/ml at day 5 after treatment. In stool, 24h 
post-administration virus genomes were detected in 4 out of 4 patients analyzed (patients #09, 
#010, #011, and #012, 5.89x104genomes/g ± 4.35x104genomes/g); 48h post-administration virus 
was detected in 2 (#09 and #012) out of 3 (patients #09, #010 and #012) analyzed 
(6.98x104genomes/g ± 3.90x104genomes/g); and at day 5 post-administration virus was detected 
in 1 (patient #013) out of 3 (patients #09, #012 and #013), but did not reach a quantifiable level. 
Finally, in sputum at 24h post-administration viral genomes were detected in 2 (patients #09 and 
#010) out of 3 (patients #08, #09 and #010) samples analyzed (6.09x104genomes/ml ± 
5.87x104genomes/ml); at 48h post-administration in 2 (patients #010 and #012) out of 4 (patients 
#08, #09, #010 and #012) samples analyzed (3.43x104genomes/ml and one not quantifiable); and 
at day 5 post-administration in 1 (patient #012) out of 5 (patients #08, #09, #010, #012, and #013) 
samples analyzed (3.91x104genomes/ml). All samples from days 12, 19, and 26 were negative.  
 
Cytokine analysis 
Analysis of serum IL6 and IL10 levels was performed before and after treatment (6h, 24h, 48h, 
day 5, day 12, day 19, day 26 post-ICOVIR-5 administration) (Fig 3). An increase of IL6 levels was 
detected for all patients in the first 24h post-administration, likely reflecting an early innate 
immune response against the virus. At 6h post-administration, there was a correlation between 
 15 
the viral dose used and the IL6 level detected (22.6 pg/ml for 1x1011vp, 28.8 pg/ml for 3.3x1011vp, 
31.5 pg/ml for 1x1012vp, 49.9 pg/ml for 3.3x1012vp, and a mean of 303 pg/ml for 1x1013vp; lineal 
regression IL6 concentration versus amount of ICOVIR-5 administered, r=0.97 p<0.005). The peak 
of IL6 level observed for most patients was lower than 100 pg/ml. Only 3 patients showed a peak 
higher than 200 pg/ml (patients #01, #08, #010). Among them, only in patient #08 (1x1013vp) this 
higher IL6 elevation was accompanied with a dose-limiting toxicity, as a transaminitis grade 3 at 
24h post-treatment. Serum IL10 was also measured as it is another biomarker of inflammation 
commonly detected upon systemic adenovirus administrations, although with anti-inflammatory 
properties contrary to the pro-inflammatory IL6. A peak of IL10 was detected in all patients, 
reaching higher levels with higher doses. As previously reported, the peak of IL10 (24h) was 
delayed compared to IL6 (6h). 15 At 24h post-administration, there was a correlation between the 
viral dose and the IL-10 level detected (lineal regression IL10 concentration versus amount of 
ICOVIR-5 administered, r=0.81; p<0.05). Patient #013 (1x1013vp) had the highest IL10 peak (530 
pg/ml) and showed a dose-limiting toxicity as a transaminitis grade 3 at 24h post-treatment. 
There was a correlation of IL6 levels at 6h and IL10 at 24h (r=0.93; p<0.05).  
 
Detection of ICOVIR-5 in tumor biopsies 
One core needle biopsy (CNB) was obtained from skin lesions of cutaneous melanoma patients 
and liver lesions of uveal melanoma patients. Biopsies were obtained at day 5 post-treatment in 
patients treated with 1x1011vp, 3.3x1011vp, 3.3x1012vp, and 3 (patients #09, #011 and #013) out of 
the 6 patients from the highest dose of 1x1013vp. DNA was extracted from biopsies and the 
presence of viral genomes analyzed by qPCR using specific primers for ICOVIR-5. Virus DNA in 
metastasis was not detected in the patient treated with the lower 1x1011vp dose. In contrast, 
virus DNA was detected in patients treated with 3.3x1011vp and 3.3x1012vp, and in 2 (patients #09 
and #011) out of 3 patients from the highest 1x1013vp dose (Table 3). In these 2 patients the 
presence of virus DNA in blood at the time of biopsy (day 5 post-administration) precludes a clear 
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conclusion on tumor transduction. However, in the 2 patients with lower virus doses (3.3x1011vp 
and 3.3x1012vp) no viral DNA was detected in peripheral blood at day 5 post-administration 
suggesting that the detected virus derives from tumor cells and not from blood.  
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DISCUSSION 
The use of oncolytic viruses to treat cancer, known as virotherapy, is an old idea born after the 
observation of cancer remissions upon viral infections. 16 After up and downs, the concept has 
been revisited in the last 20 years using viruses, such as Vaccinia Virus, Herpes Simplex Virus 
(HSV), Measles, and Adenoviruses (Ad), designed to target and replicate more selectively in 
cancer cells, and wild type viruses with a natural selectivity for tumor cells such as Reovirus, 
Parvovirus, or Coxsackievirus A21, among others. Intratumoral injection of these viruses in 
patients has proven the concept that when a virus reaches a tumor mass it can cause tumor lysis. 
17 However, tumor targeting upon systemic administration is still a challenge. 
 
This first-in-humans phase 1 study shows that the intravenous administration of the conditionally 
replicative adenovirus ICOVIR-5 is well tolerated. A dose of 1x1013vp of ICOVIR-5 induced 
transaminitis in 2 out of 6 patients, and thrombocytopenia in one of them, while a dose of 
3.3x1012vp can be safely administered without DLT. The primary objective of the trial was to 
recommend a phase II dose. According to the protocol, the dose level in which no DLT was 
observed would be taken as a safe dose level and therefore the recommended phase II dose. Our 
results indicate that for ICOVIR5 this dose is 3.3x1012 vp. Mild liver toxicity has been previously 
described with similar intravenous administered viruses. 15, 18, 19  ICOVIR-7, an oncolytic 
adenovirus similar to ICOVIR-5, produced up to grade 2 liver transaminases elevation in 13 of 21 
patients, although most of the patients received treatment by intratumoral injection and only 3 
intravenously. 20 For ICOVIR-5 transaminitis was the main toxicity limiting the dose escalation 
beyond the 1x1013vp dose. This transient transaminitis observed in 2 patients, started at days 1 
and 5 post-treatment, and persisted for 1 and 7 days, respectively.  
 
Systemic administration has been attempted in clinical trials using Newcastle Disease Virus HSV, 
reovirus, picornavirus, measles, Vaccinia Virus 21 and adenovirus. 19 Out of eight evaluated 
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patients in a recent trial of an oncolytic Vaccinia Virus administered systemically, two proved 
positive for virus in biopsy. 21 Still, the inadequate viral delivery was identified as a main factor for 
insufficient antitumor efficacy. Adenovirus has been extensively used in gene therapy and 
virotherapy clinical trials. Among several clinical trials with systemically administered Onyx015 
only occasional and transient responses were observed in some colorectal carcinoma patients. 22, 
23 With CG7870, an oncolytic adenovirus designed for prostate carcinoma with E1A under the 
probasin promoter and E1B under the PSA promoter, the serum PSA level dropped 25% to 49% 
transiently in 5 out of the 23 intravenously treated patients, 4 of them at the highest doses 
(6x1011 to 6x1012 vp). 19 Focusing on tumor targeting, occasional evidence for systemic tumor 
targeting has been reported. Reid et al. injected ONYX-015 intra-arterially in 11 patients with liver 
metastases of colorectal cancer and biopsies at day 4 post-infusion resulted negative for virus. 22 
Similar results were obtained in the phase II trial after infusing 2x1012vp as a maximum feasible 
dose on multiple days (1, 8, 22, 50, and 78). 23 It was concluded that improving delivery and 
replication efficiency would be needed to obtain evidences of intratumoral replication.  Hamid et 
al. infused intravenously ONYX-015 to 18 patients with liver metastases of colorectal carcinoma. 
18 The autopsy of one patient that died 56 h after virus administration showed very few cells 
positive for virus in the tumors. Nemunaitis et al. infused ONYX-015 intravenously in 10 patients 
with lung metastases reaching much higher doses (up to 2x1013vp). One analyzed biopsy in a 
patient treated with 2x1012vp resulted positive for virus presence 5 days post-infusion. 15 A more 
potent virus, CG7870, where E1A and E1b were regulated by the probasin and the PSA promoters 
respectively, was infused intravenously in prostate carcinoma patients up to a dose of 6x1012vp, 
identified as the MTD, but no biopsies were analyzed for tumor targeting. 19  Lack of antitumor 
efficacy in these clinical trials led to abandon the systemic approach with oncolytic adenoviruses 
based on adenovirus serotype 5 with an unmodified capsid. After an interval of several years, a 
survey of clinical trials ongoing in 2014 identified ICOVIR-5, ColoAd1, and VCN01 (all of them with 
capsids different from Ad5-wild type) as oncolytic Ads used intravenously, and no additional 
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adenoviruses were added to this list in 2015. 24, 25 However, the Ad-D24RGD oncolytic adenovirus, 
with the same RGD-modified capsid as ICOVIR-5, has been used intratumorally 26, 
intraperitoneally 27,  and in a combination of intratumoral and intravenous routes 20, 28. Evidence 
of systemic tumor targeting in non-injected tumors distant from injected tumors was observed in 
an autopsy of one patient (C200) that died 19 days after injection in multiple tumor sites. 28 With 
regard to oncolytic adenoviruses with other capsid modifications, metastatic tumor targeting has 
been demonstrated in a patient treated intravenously with a serotype 5/3 chimeric fiber. 28 The 
biodistribution analysis in patient autopsy samples indicated a fair capability of tumor targeting of 
oncolytic adenoviruses even when injected intratumorally. 28 This consistent detection of virus in 
occasional patient autopsies suggests that the small samples that can be analyzed in a biopsy may 
underestimate the tumor targeting potential of the virus. In this context it is noteworthy our 
detection of viral genomes in four out of seven analyzed biopsies, in two cases with a negative 
viremia. The same can be concluded from the more frequently reported observation of secondary 
peaks of viremia compared to positive biopsies, which suggest virus replication in tumors. We did 
not observe secondary peaks of viremia even in the four patients where the virus had been 
detected in the tumor at day 5. In two patients (#012 and #013) viremia levels were positive until 
the end of the study (day 26). Among them, one (patient #013) had a tumor biopsy analyzed at 
day 5 and it resulted negative. Although preliminary, our results indicate that the presence of 
virus in the tumor does not necessarily leads to secondary peaks of viremia.   
 
In our study, pharmacokinetics analysis indicates that there is a correlation between exposure 
and the administered dose, since larger doses lead to longer time to virus elimination. In addition, 
the study shows that the virus shedding is also dose-dependent: the presence of the virus is 
higher in the last dose level, but at the recommended dose level it is found in blood and sputum 
at 48 hours, indicating effective spread of the virus. The analysis shows that neutralizing antibody 
titers were not dose-dependent and pretreatment levels did not correlate with tumor response. 
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All patients had an early onset of innate immune response, with a correlation between dose and 
levels of IL6. As reported, the peak of IL10 was delayed compared to IL6. IL6 and IL10 levels 
correlated with the dose and between them. Patients with grade 3 transaminitis (patients #08 
and #013) showed highest peaks of IL6 and IL10. This toxicity was very short in time and no 
systemic inflammatory response syndrome was observed.  
 
As a most relevant finding, viral genomes were detected in the biopsy of metastatic lesions of 
four patients, indicating that oncolytic adenovirus can achieve tumor targeting of metastases 
upon intravenous administration. With regards to clinical activity, no tumor responses were 
observed, but 7 stabilizations of disease were seen out of 11 patients, 5 of them among the 6 
patients treated at the highest dose.  Despite this low antitumor activity, the longer survival of 
uveal melanoma patients compared to cutaneous melanoma patients was intriguing as the 
expected survival before the emergence of targeted therapy (BRAF/MEK inhibitors) and anti-PD1 
antibodies for those patients should be the same. 29 Although the number of patients is very small 
and definitive conclusions cannot be taken, this trend suggests a superior activity of systemic 
ICOVIR5 against metastatic uveal melanoma compared to metastatic cutaneous melanoma. 
It could be speculated that this could be related to the shared hepatotropism of adenovirus and 
uveal melanoma metastases or/and that uveal melanoma liver metastases are more prone to be 
controlled by the immune system once infected by the virus. Low antitumor efficacy has been 
previously reported with oncolytic adenoviruses. By intratumoral administration head and neck 
patients ONYX-015 produced 3 partial and 2 minor responses and 8 disease stabilizations. 30 In 23 
pancreatic cancer patients produced six minor responses and 10 stabilizations. 31  In the phase 1 
study of intratumoral Telomelysin in various solid tumors, one partial and seven stable disease 
responses were reported. 32 By intraperitoneal injection of Ad5-∆24-RGD, 15 disease stabilizations 
were observed among 21 malignant gynecologic patients. 27Finally, among 35 non-invasive 
bladder cancer patients receiving CG0070 intravesically, 17 showed complete responses. 33 By 
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intravenous administration, ONYX-015 induced one mixed response and 9 disease stabilizations in 
10 patients. 15 In a subsequent phase II trial, seven out to 18 patients experienced stable disease. 
18 Systemic administration of CG7870 in 23 prostate cancer patients induced some decrease in 
serum PSA in 5 patients, with no complete or partial PSA responses. 19 With ICOVIR7 20, out of two 
evaluated patients that were treated only by the intravenous route, one head and neck tumor 
patient had a 10% decrease of tumor size.  
There is little experience with oncolytic adenoviruses applied to melanoma, and none after 
systemic administration alone. When oncolytic adenovirus Ad5/3-D24-GMCSF was administered 
to 9 patients with melanoma (50% of dose intratumoral and 50% intravenous), one out of four 
evaluable patients showed a minor response (15% size decrease) in an injected lesion. 34  
Our study adds interesting information to the development of virotherapy with oncolytic 
adenoviruses. One point of growing interest is the potential combination of oncolytic viruses with 
immunotherapy, as the virus-induced immune response may favor the infiltration of lymphocytes 
in tumors. In this setting, it is imperative for the virus to reach all tumor sites systemically to 
promote the infiltration on “cold” tumors characterized by the lack of tumor-infiltrating 
lymphocytes. Our results indicate that systemic tumor targeting of metastases with oncolytic 
adenoviruses is feasible using the intravenous administration route. Although armed oncolytic 
adenoviruses may be needed to obtain sufficient tumor debulking by oncolysis before antiviral 
immunity neutralizes the virus, our results encourage further studies by systemic administration. 
We are currently exploring the use of a hyaluronidase-armed oncolytic adenovirus (VCN-01) with 
a slightly different capsid than ICOVIR-5 (RGD in the fiber shaft instead of the HI-loop) by systemic 
administration in cancer patients.  
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Figure 1. Quantification of ICOVIR-5 pharmacokinetics in blood by Real-Time PCR. In dose levels 
1a, 2a, 3a and 4a only viral dose are indicated. For dose level 5a, patient number identification is 
also indicated. The dashed lines represent the lower limit of quantification of ICOVIR-5 genomes 
in blood. Samples were analyzed in triplicates. 
Figure 2. Quantification of ICOVIR-5 genomes in high-dose patients (1x1013vp) by Real-Time PCR 
in: A) Blood, B) Urine, C) Stool and D) Sputum. The dashed lines represent the lower limit of 
quantification (LOQ) and detection (LOD) of ICOVIR-5 genomes. Samples were analyzed in 
triplicates. # : Sample detectable but not quantifiable. 
Figure 3. Analysis of IL6 and IL10 in serum samples by ELISA. Analysis of IL6 (A) and IL10 (B) in 
serum samples on days 0, 1, 2, 5, 12, 19 and 26 post-ICOVIR-5 administration. Samples were 
analyzed in triplicates. 
 
 
Figure 1. García et al
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Supplementary figure 1.  Kaplan-Meier survival analysis of cutaneous (n=4) vs uveal (n=6) 
melanoma patients.  
Table 1. Dose levels and DLTs 
Patient Dose (vp) Level Toxicity DLT Decision taken by investigators’ committee 
#01 1x1011 1a 
Grade 3 lymphopenia 
Grade 2 neutropenia  
No 
Grade 3 toxicity not associated to treatment 
Decision: escalation to the next level 
#02 3.3x1011 2a Grade 3 asthenia  No 
The patient did not complete the cycle. 
Decision: replacement of patient 
#03 3.3x1011 2a Grade 1 toxicity No Decision: escalation to the next level 
#04 1x1012 3a Grade 2 thrombocytopenia No 
Grade 3 thrombocytopenia out of the cycle. 
By relevance, the decision is replacement of 
patient. 
#06 1x1012 3a Grade 3 neutropenia No 
Transient (<24 hours) grade 3 toxicity. 
Decision: escalation to the next level 
#07 3.3x1012 4a < Grade 2 toxicity No 
Grade 2 unrelated asthenia  
Decision: escalation to the next level 
#08 1x1013 5a 
Grade 3 transaminitis 
Grade 3 thrombocytopenia 
Yes Expansion of cohort by DLT 
















#13 1x1013 5a Grade 3 transaminitis Yes 
End of study due to two DLT. 
MTD declared level 
Vp: viral particles, DLT: dose limiting toxicity; MTD: maximum tolerated dose 
 
Table 2. Number of patients with nonhematologic toxicity, considering the worst 
grade toxicity for each patient (n=12). 
                                                                                                    Toxicity (grade) 
Symptoms 1 2 3 4 
Fever 8 1 0 0 
Stomatitis 1 1 0 0 
Myalgia/arthralgia 2 1 0 0 
Headache 1 0 0 0 
Asthenia 4 2 1 0 
Rash 2 0 0 0 
Diarrhea 1 0 0 0 
Constipation 1 0 0 0 
Hypertension 1 1 0 0 
Edema 1 0 1 0 
Nausea/ Vomiting 2 0 0 0 
Renal failure 0 1 0 0 
Chills 2 0 0 0 
Transaminitis 0 1 2 0 
Hypocalcemia 0 1 0 0 
Hypophosphatemia 0 1 0 0 
Hypomagnesemia 1 0 0 0 
Hypokalemia 1 0 0 0 
 
Table 3. Anti-Ad5 neutralizing antibodies, clinical responses, and viral genomes in biopsies. 











blood (day 5) 
(genomes/ml) 
#001 (CM) 1x1011vp/ml 1/1280 >1/5120 PD negative   negative 
#003 (UM) 3.3x1011vp/ml 1/10 1/2560 SD (100) positive 1.04x103 negative 
#004 (CM) 1x1012vp/ml 1/1280 >1/5120 PD  negative 
 
        negative 
#006 (UM) 1x1012vp/ml 1/80 >1/5120 SD (433) NA 
  #007 (CM) 3.3x1012vp/ml 1/160 >1/5120 PD positive 3.89x102 negative 
#008 (UM) 1x1013vp/ml 1/80 >1/5120 PD NA 
  #009 (CM) 1x1013vp/ml 1/10 1/1280 SD (56) positive 1.47x105 1,84x104 
#010 (UM) 1x1013vp/ml 1/320 >1/5120 SD (94) NA 
  #011 (UM) 1x1013vp/ml 1/320 >1/5120 SD (131) positive 1.65x102 9.65x105 
#012 (UM) 1x1013vp/ml 1/640 >1/5120 SD (84) NA 
  #013 (CM) 1x1013vp/ml 1/10 1/1280 SD (112) negative   2.23x106 
Patient: CM, cutaneous melanoma; UM, uveal melanoma. Nabs: anti-adenovirus neutralizing antibodies. >1/5120 upper limit of 
detection, Vp: viral particles, PD: progressive disease, SD: stable disease (until day indicated); NA: not available. 
 
